Genetically adjusted PSA levels for prostate cancer screening

Prostate-specific antigen (PSA) screening for prostate cancer remains controversial because it increases overdiagnosis and overtreatment of clinically insignificant tumors. Accounting for genetic determinants of constitutive, non-cancer PSA variation has potential to improve screening utility. We discovered 128 genome-wide significant associations (P<5×10-8) in a multi-ancestry GWAS meta-analysis of 95,768 men and developed a PSA polygenic score (PGSPSA) that explains 9.61% of constitutive PSA variation. Here we provide full GWAS summary statistics for the multi-ancestry meta-analysis and ancestry-stratified summary statistics for ~1.2 million variants used to derive a genome-wide PGSPSA.